Profile data is unavailable for this security.
About the company
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
- Revenue in USD (TTM)0.00
- Net income in USD-24.14m
- Incorporated2008
- Employees23.00
- LocationContraFect Corp28 Wells Avenue, 3rd FloorYONKERS 10701United StatesUSA
- Phone+1 (914) 207-2300
- Fax+1 (302) 636-5454
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pure Harvest Corporate Group Inc | 2.48m | -6.67m | 169.28k | 25.00 | -- | 0.1115 | -- | 0.0684 | -0.0901 | -0.0901 | 0.0383 | 0.0201 | 0.2644 | 1.46 | 40.64 | 99,070.40 | -70.96 | -- | -136.76 | -- | 33.83 | -- | -268.37 | -- | 0.5886 | -0.866 | 0.7639 | -- | 1,808.41 | -- | -459.26 | -- | -- | -- |
| CNBX Pharmaceuticals Inc | 540.25k | -1.23m | 177.33k | 2.00 | -- | -- | -- | 0.3283 | -0.0583 | -0.0583 | 0.0237 | -0.0758 | 1.73 | -- | -- | 270,125.00 | -393.70 | -73.32 | -- | -99.80 | 6.37 | -- | -228.08 | -3,970.88 | -- | -1.37 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
| Cannabis Global, Inc. | 2.62m | -3.16m | 186.59k | 3.00 | -- | 0.0086 | -- | 0.0712 | -0.0324 | -0.0324 | 0.008 | 0.0058 | 0.1929 | 14.13 | 5.92 | -- | -27.77 | -164.57 | -140.92 | -- | -2.45 | -- | -143.95 | -831.07 | 0.1799 | -1.75 | 0.3238 | -- | 5,829.78 | -- | -58.94 | -- | -- | -- |
| Black Bird Biotech Inc | 36.33k | -836.14k | 196.81k | 4.00 | -- | -- | -- | 5.42 | -0.0018 | -0.0018 | 0.00005 | -0.0005 | 0.2718 | 0.3178 | 13.31 | 9,082.50 | -625.64 | -433.36 | -- | -- | 27.55 | -- | -2,301.51 | -1,800.06 | 0.0154 | -0.6032 | -- | -- | -20.96 | -- | 8.42 | -- | -- | -- |
| Athersys Inc | 80.00k | -37.51m | 197.50k | 24.00 | -- | -- | -- | 2.47 | -2.03 | -2.03 | 0.004 | -1.36 | 0.0037 | -- | 0.2424 | 3,333.33 | -174.57 | -120.93 | -- | -206.72 | -- | -- | -46,883.75 | -727.72 | -- | -- | -- | -- | -3.43 | 7.51 | 16.58 | -- | 6.85 | -- |
| Propanc Biopharma Inc | 0.00 | -2.46m | 209.97k | 1.00 | -- | -- | -- | -- | -0.3033 | -0.3033 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -2,440.90 | -4,945.87 | -- | -- | -- | -- | -- | -- | -- | -1.70 | -- | -- | -- | -- | -17.63 | -- | -- | -- |
| Gelstat Corp | 1.68m | -1.22m | 210.00k | 2.00 | -- | 0.0287 | -- | 0.125 | -0.0033 | -0.0033 | 0.0046 | 0.014 | 0.3021 | 4.17 | -- | 840,285.00 | -21.96 | -- | -26.29 | -- | 28.99 | -- | -72.69 | -- | 0.3216 | -134.79 | 0.0267 | -- | -66.81 | -- | -60.17 | -- | -- | -- |
| ContraFect Corp | 0.00 | -24.14m | 223.73k | 23.00 | -- | -- | -- | -- | -19.25 | -19.25 | 0.00 | -0.538 | 0.00 | -- | -- | 0.00 | -150.12 | -74.17 | -- | -94.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -221.24 | -- | -- | -- |
| Limitless Venture Group Inc | 0.00 | -10.68m | 253.92k | -- | -- | -- | -- | -- | -117.82 | -117.82 | 0.00 | -9.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -37.95 | -- | -- | -- | -- | -- | -- | -- | -- |
| Bioquest Corp | 0.00 | -507.41k | 260.72k | -- | -- | -- | -- | -- | -0.0485 | -0.0485 | 0.00 | -0.0467 | 0.00 | -- | -- | -- | -3,483.76 | -- | -- | -- | -- | -- | -- | -- | -- | -3.88 | -- | -- | -- | -- | 64.67 | -- | -- | -- |
| Emo Capital Corp | -100.00bn | -100.00bn | 286.50k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -0.0017 | -- | -- | -- | -- | -- | -7,495.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -138.44 | -- | -- | -- |
| Baudax Bio Inc | 310.00k | -25.83m | 294.25k | 9.00 | -- | -- | -- | 0.9492 | -17.25 | -9.17 | 0.0778 | -0.0985 | 0.0163 | -- | -- | 34,444.45 | -135.61 | -112.14 | -- | -192.87 | -1,445.81 | -- | -8,331.61 | -9,179.73 | -- | -- | 1.30 | -- | 17.50 | -- | -164.95 | -- | -56.52 | -- |
| DMK Pharmaceuticals Corp | 3.62m | -21.16m | 295.99k | 11.00 | -- | -- | -- | 0.0818 | -8.69 | -9.18 | 1.04 | -0.4918 | 0.3432 | 5.66 | 5.54 | 329,062.70 | -200.59 | -79.00 | -- | -113.05 | -37.30 | 4.85 | -584.50 | -347.59 | 0.5355 | -- | -- | -- | 115.34 | -18.31 | 24.28 | -- | -20.10 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 1.40m | 13.03% |
| Old Point Trust & Financial Services, NA (Invt Mgmt)as of 31 Mar 2024 | 6.00 | 0.00% |
| XTX Markets LLCas of 31 Mar 2024 | 0.00 | 0.00% |
